Last update 30 May 2025

Careseng 1370

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Target-
Action-
Mechanism-
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases
Active Indication-
Inactive Indication
Advanced Lung Non-Small Cell CarcinomaBone marrow depressionChemotherapy-induced myelosuppression
Originator Organization
Careseng Biotech Co. Ltd.
Active Organization-
Inactive Organization
Careseng Biotech Co. Ltd.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Careseng 1370
NCT03974516
/ TerminatedPhase 1
A Phase I Dose-Escalation Study in Healthy Volunteers to Evaluate the Safety and Tolerability Profiles of Careseng 1370
NCT03692780
/ WithdrawnPhase 1/2
A Phase I Dose-Finding Followed by Phase IIa Randomized, Double-Blind, Placebo-Controlled, Parallel, Add-on to Cisplatin Plus Docetaxel Study to Evaluate the Safety, Tolerability and Efficacy Profiles of Careseng 1370 to Treat Chemotherapy-Induced Myelosuppression in Advanced Non-Small Cell Lung Cancer (NSCLC) Subjects
100 Clinical Results associated with Careseng 1370
Login to view more data
100 Translational Medicine associated with Careseng 1370
Login to view more data
100 Patents (Medical) associated with Careseng 1370
Login to view more data
100 Deals associated with Careseng 1370
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 2-
Careseng Biotech Co. Ltd.
01 Mar 2019
Bone marrow depressionPhase 2-
Careseng Biotech Co. Ltd.
01 Mar 2019
Chemotherapy-induced myelosuppressionPhase 2-
Careseng Biotech Co. Ltd.
01 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03974516 (CTgov)
Phase 1
Chemotherapy-induced myelosuppression
13
(Careseng 1370 Level A)
uimxpqvmgp = hzpkcxsqsr gmoulktcmg (khzbetbbhk, klpauoxkqa - mwdtexpqxk)
View more
-
22 Nov 2024
(Careseng 1370 Level B)
uimxpqvmgp = cphjzzwakp gmoulktcmg (khzbetbbhk, kbdnbqboph - wusflskuxd)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free